Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Humanigen, Inc. - Common Stock (NQ:HGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Humanigen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)
From Humanigen, Inc.
Via Business Wire
European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19
From Humanigen, Inc.
Via Business Wire
Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM‘21
From Humanigen, Inc.
Via Business Wire
Expert Ratings For Humanigen
Over the past 3 months, 4 analysts have published their opinion on Humanigen (NASDAQ: 
Via Benzinga
Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab
From Humanigen, Inc.
Via Business Wire
Humanigen’s Budget Impact Model Demonstrates Lenzilumab’s Potential Positive Economic Value in Hospitalized COVID-19 Patients
From Humanigen, Inc.
Via Business Wire
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe
From Humanigen, Inc.
Via Business Wire
NASDAQ:HGEN Investor Notice: Investigation over Potential Securities Laws Violations by Humanigen, Inc.
San Diego, CA -- (SBWIRE) -- 10/07/2021 -- An investigation was announced over potential securities laws violations by Humanigen, Inc. in connection with certain financial statements. 
Via SBWire
Humanigen Announces Participation and Presentation at Multiple Conferences in October
From Humanigen, Inc.
Via Business Wire
Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK’s MHRA
From Humanigen, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021
From Humanigen, Inc.
Via Business Wire
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for Lenzilumab
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in September
From Humanigen, Inc.
Via Business Wire
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
60 Biggest Movers From Friday
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in... 
Via Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Hepion Pharmaceuticals (NASDAQ:HEPA 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 63.11% to $14.18 during Friday's regular session. IVERIC bio's stock is trading at a volume of 120.3 million... 
Via Benzinga
Why Humanigen Stock Is Sinking Today
The Food and Drug Administration turned down Emergency Use Authorization of lenzilumab in treating hospitalized COVID-19 patients. 
Via The Motley Fool
After FDA Rejection This Biopharma Stock Garners Analyst Downgrades, Price Cuts
JPMorgan 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Gevo Shares Spike Higher
Toward the end of trading Thursday, the Dow traded down 0.37% to 34,901.89 while the NASDAQ fell 0.03% to 15,281.73. The S&P also rose, gaining 0.31% to 4,499.94. The U.S. has... 
Via Benzinga
Topics Stocks
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE: 
Via Benzinga
Stocks Inch Higher as Dow Looks to Snap Skid
The Dow Jones Industrial Index is up 68 points midday and on track to snap a three-day losing streak. 
Via Talk Markets
Topics Stocks
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Impel NeuroPharma (NASDAQ:IMPL) shares increased by 22.16% to $20.29 during Thursday's regular session. Trading volume for this security as of 12:30 EST is 1.1... 
Via Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Rocket Lab USA, Inc. (NASDAQ: RKLB) jumped 37.3% to settle at $20.72. Rocket Lab reported 1H sales of $29.5 million and announced it has been awarded a contract to deploy... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.